Want to see PRLD full AI Analyst Report?
PRLD Stock Chart & Stats
$3.89
$0.75(19.28%)
At close: 4:00 PM EDT
$3.89
$0.75(19.28%)
Day’s Range― - ―
52-Week Range$0.98 - $6.83
Previous Close$4.6
Volume1.86M
Average Volume (3M)256.05K
Market Cap
$516.33M
Enterprise Value$390.30
Total Cash (Recent Filing)$151.76M
Total Debt (Recent Filing)$17.65M
Price to Earnings (P/E)―
Beta0.89
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding65,075,350
10 Day Avg. Volume194,393
30 Day Avg. Volume256,051
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)3.25
Price to Sales (P/S)18.38
P/FCF Ratio-3.96
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$8.00Price Target Upside105.66% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Rapid Revenue ScalingRevenue growth indicates increasing collaboration or licensing activity and expanding commercial interest in the pipeline. Sustained growth could improve operating leverage over time, although the company remains pre-commercial.
High Gross MarginThe very high reported gross margin suggests favorable economics on collaboration-derived revenue. If this revenue base expands, it could provide meaningful support for future development spending and improve the path toward eventual profitability.
Conservative LeverageModest debt relative to equity limits near-term balance-sheet pressure and preserves financing flexibility. The larger equity base can support continued clinical development, though future funding may still dilute shareholders.
Bears Say
Deep Operating LossesLarge operating and net losses show that current revenue is insufficient to fund research, development, and corporate costs. Continued losses increase dependence on successful clinical progress, partnerships, or additional capital.
Persistent Cash BurnAlthough cash consumption has improved from prior years, operations remain far from self-funding. Persistent negative free cash flow can constrain pipeline investment and require recurring external financing before products generate meaningful cash.
Pre-Commercial Business ModelWithout marketed products, revenue depends on partner agreements, milestones, and licensing events that may be uneven or uncertain. This creates funding and execution risk until a candidate reaches commercialization and recurring product sales.
Prelude Therapeutics News
PRLD FAQ
What was Prelude Therapeutics’s price range in the past 12 months?
Prelude Therapeutics lowest stock price was $0.98 and its highest was $6.83 in the past 12 months.
What is Prelude Therapeutics’s market cap?
Prelude Therapeutics’s market cap is $516.33M.
When is Prelude Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Prelude Therapeutics’s earnings last quarter?
Currently, no data Available
Is Prelude Therapeutics overvalued?
According to Wall Street analysts Prelude Therapeutics’s price is currently Undervalued.
Does Prelude Therapeutics pay dividends?
Prelude Therapeutics does not currently pay dividends.
What is Prelude Therapeutics’s EPS estimate?
Prelude Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Prelude Therapeutics have?
Prelude Therapeutics has 65,075,350 shares outstanding.
What happened to Prelude Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Prelude Therapeutics?
Currently, no hedge funds are holding shares in PRLD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Prelude Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.00 (105.66% Upside)
$8.00 (105.66% Upside)
Blogger Sentiment
Bullish
PRLD Sentiment 100%
Sector Average 61%
Sector Average 61%
Hedge Fund Trend
Increased
By 6.5M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 5.5%
Last 30 Days ▼ 5.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-38.02%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
64.78%
Trailing 12-Months
Company Description
Prelude Therapeutics
Prelude Therapeutics, Inc. is a clinical-stage precision oncology company focused on identifying and developing innovative, targeted cancer treatments for patient populations with unmet medical needs. Its pipeline includes PRT543, currently undergoing Phase 1 clinical evaluation for certain solid tumors and myeloid malignancies. Another asset, PRT811, is also in Phase 1 trials, targeting various solid tumors, notably glioblastoma multiforme. The company is additionally progressing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a powerful and highly kinome-selective CDK9 inhibitor; PRT-SCA2, which is in preclinical development for several genomically selected cancers; PRT3645, a brain-penetrant molecule that precisely and effectively targets CDK4/6; and PRT-K4, another preclinical compound for solid tumors. Founded in 2016, the firm's headquarters are located in Wilmington, Delaware.
PRLD Stock 12 Month Forecast
Average Price Target
$8.00
▲(105.66% Upside)
Technical Analysis
Ownership Overview
30.04% Insiders
1.95% Mutual Funds
48.93% Other Institutional Investors
14.90% Public Companies and
Individual Investors